Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 01 2019
30 01 2019
Historique:
received:
25
06
2018
accepted:
04
12
2018
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
11
8
2020
Statut:
epublish
Résumé
While the importance of the serotonergic system in obsessive compulsive disorder (OCD) is well established, its role in Tourette syndrome (TS) is uncertain. Particularly in TS patients with comorbid OCD (TS + OCD), decreased serotonin transporter (SERT) binding has been suggested. Here, we investigated for the first time SERT binding in TS patients with and without OCD (TS - OCD) compared to both healthy controls (HC) and OCD patients as well as the influence of escitalopram using the potent SERT imaging ligand [
Identifiants
pubmed: 30700759
doi: 10.1038/s41598-018-37710-4
pii: 10.1038/s41598-018-37710-4
pmc: PMC6353942
doi:
Substances chimiques
Serotonin Plasma Membrane Transport Proteins
0
Citalopram
0DHU5B8D6V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
972Commentaires et corrections
Type : ErratumIn
Références
Heinz, A. et al. Tourette’s syndrome: [I-123] beta-CIT SPECT correlates of vocal tic severity. Neurology 51, 1069–1074 (1998).
pubmed: 9781531
doi: 10.1212/WNL.51.4.1069
Müller-Vahl, K. R. et al. Serotonin transporter binding in Tourette Syndrome. Neurosci. Lett. 385, 120–125 (2005).
pubmed: 15936877
doi: 10.1016/j.neulet.2005.05.031
Wong, D. F. et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 33, 1239–1251 (2008).
doi: 10.1038/sj.npp.1301528
Zitterl, W. et al. [123I]-??-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 32, 1661–1668 (2007).
pubmed: 17192774
doi: 10.1038/sj.npp.1301290
Hasselbalch, S. G. et al. Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. Acta Psychiatr. Scand. 115, 388–394 (2007).
pubmed: 17430417
doi: 10.1111/j.1600-0447.2006.00940.x
Hesse, S. et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. - Neuroimaging 140, 63–72 (2005).
doi: 10.1016/j.pscychresns.2005.07.002
Hesse, S. et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 14, 606–617 (2011).
pubmed: 21232166
doi: 10.1017/S1461145710001604
Reimold, M. et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - A [11C]DASB PET study. J. Neural Transm. 114, 1603–1609 (2007).
pubmed: 17713719
doi: 10.1007/s00702-007-0785-6
Matsumoto, R. et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: A [11C]DASB PET study. Neuroimage 49, 121–126 (2010).
pubmed: 19660554
doi: 10.1016/j.neuroimage.2009.07.069
Kim, E. et al. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study. Psychol. Med. 46, 357–366 (2016).
pubmed: 26423910
doi: 10.1017/S0033291715001865
Simpson, H. B. et al. Serotonin transporters in obsessive-compulsive disorder: A positron emission tomography study with [11C]McN 5652. Biol. Psychiatry 54, 1414–1421 (2003).
pubmed: 14675806
doi: 10.1016/S0006-3223(03)00544-4
Van Der Wee, N. J. et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]β-CIT SPECT. Am. J. Psychiatry 161, 2201–2206 (2004).
pubmed: 15569890
doi: 10.1176/appi.ajp.161.12.2201
Pogarell, O. et al. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol. Psychiatry 54, 1406–1413 (2003).
pubmed: 14675805
doi: 10.1016/S0006-3223(03)00183-5
Zitterl, W. et al. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 33, 3126–34 (2008).
pubmed: 18354388
doi: 10.1038/npp.2008.35
Stengler-Wenzke, K. et al. Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder. Neuropsychobiology 53, 40–45 (2006).
pubmed: 16397403
doi: 10.1159/000090702
Gryglewski, G., Lanzenberger, R., Kranz, G. S. & Cumming, P. Meta-analysis of molecular imaging of serotonin transporters in major depression. Journal of Cerebral Blood Flow and Metabolism 34, 1096–1103 (2014).
pubmed: 24802331
pmcid: 4083395
doi: 10.1038/jcbfm.2014.82
Maron, E. et al. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur. Arch. Psychiatry Clin. Neurosci. 254, 392–396 (2004).
pubmed: 15538601
doi: 10.1007/s00406-004-0520-3
van der Wee, N. J. et al. Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT. J. Nucl. Med. 49, 757–763 (2008).
pubmed: 18413401
doi: 10.2967/jnumed.107.045518
Oya, S. et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): An improved serotonin transporter ligand. Nucl. Med. Biol. 27, 249–254 (2000).
pubmed: 10832081
doi: 10.1016/S0969-8051(00)00084-6
Lin, K.-J. et al. Brain SPECT imaging and whole-body biodistribution with [(123)I]ADAM - a serotonin transporter radiotracer in healthy human subjects. Nucl. Med. Biol. 33, 193–202 (2006).
pubmed: 16546673
doi: 10.1016/j.nucmedbio.2005.10.006
Butler, I. J., Koslow, S. H., Seifert, W. E., Caprioli, R. M. & Singer, H. S. Biogenic amine metabolism in tourette syndrome. Ann. Neurol. 6, 37–39 (1979).
pubmed: 292354
doi: 10.1002/ana.410060109
Singer, H. S., Tune, L. E., Butler, I. J., Zaczek, R. & Coyle, J. T. Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome. Adv. Neurol. 35, 177–183 (1982).
pubmed: 6959488
Anderson, G. M. et al. Brain Monoamines and Amino Acids in Gilles de la Tourette’s Syndrome: A Preliminary Study of Subcortical Regions. Archives of General Psychiatry 49, 584–586 (1992).
pubmed: 1378261
doi: 10.1001/archpsyc.1992.01820070078016
Comings, D. E. Blood serotonin and tryptophan in Tourette syndrome. Am. J. Med. Genet. 36, 418–430 (1990).
pubmed: 2389798
doi: 10.1002/ajmg.1320360410
Singer, H. S., Hahn, I. H., Krowiak, E., Nelson, E. & Moran, T. Tourette’s syndrome: a neurochemical analysis of postmortem cortical brain tissue. Ann. Neurol. 27, 443–446 (1990).
pubmed: 1972320
doi: 10.1002/ana.410270415
Minzer, K., Lee, O., Hong, J. J. & Singer, H. S. Increased prefrontal D2 protein in Tourette syndrome: A postmortem analysis of frontal cortex and striatum. J. Neurol. Sci. 219, 55–61 (2004).
pubmed: 15050438
doi: 10.1016/j.jns.2003.12.006
Qi, Y., Zheng, Y., Li, Z. & Xiong, L. Progress in genetic studies of tourette’s syndrome. Brain Sciences 7 (2017).
Abdulkadir, M. et al. Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. European Archives of Psychiatry and Clinical Neuroscience 1–16, https://doi.org/10.1007/s00406-017-0808-8 (2017).
Haugbol, S. et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette’s syndrome. Int J Neuropsychopharmacol 10, 245–252 (2007).
pubmed: 16945163
doi: 10.1017/S1461145706006559
Anderson, G. M. et al. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv. Neurol. 58, 123–133 (1992).
pubmed: 1414615
Lee, Y. S. et al. Performance measurement of PSF modeling reconstruction (True X) on Siemens Biograph TruePoint TrueV PET/CT. Ann. Nucl. Med. 28, 340–348 (2014).
pubmed: 24504938
doi: 10.1007/s12149-014-0815-z
Jijun, L. et al. Abnormal expression of dopamine and serotonin transporters associated with the pathophysiologic mechanism of Tourette syndrome. Neurol. India 58, 523–529 (2010).
pubmed: 20739786
doi: 10.4103/0028-3886.68663
Kugaya, A. et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 28, 413–420 (2003).
doi: 10.1038/sj.npp.1300036
SCAHILL, L. et al. Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette’s Syndrome: A Double-Blind Placebo-Controlled Study. J. Child Adolesc. Psychopharmacol. 7, 75–85 (1997).
pubmed: 9334893
doi: 10.1089/cap.1997.7.75
Frokjaer, V. G. et al. Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. J. Nucl. Med. 49, 247–254 (2008).
pubmed: 18199621
doi: 10.2967/jnumed.107.046102
Knoll, P. et al. Comparison of advanced iterative reconstruction methods for SPECT/CT. Z. Med. Phys. 22, 58–69 (2012).
pubmed: 21723716
doi: 10.1016/j.zemedi.2011.04.007
Harris, G. J. et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann. Neurol. 31, 69–75 (1992).
pubmed: 1531910
doi: 10.1002/ana.410310113
Koehler, P. R. et al. MR measurement of normal and pathologic brainstem diameters. Am. J. Neuroradiol. 6, 425–427 (1985).
pubmed: 3923800
pmcid: 8335331
Mol Debes, N. M. M., Hjalgrim, H. & Skov, L. Limited knowledge of Tourette syndrome causes delay in diagnosis. Neuropediatrics 39, 101–105 (2008).
pubmed: 18671185
doi: 10.1055/s-2008-1081457
Knoop, B. O., Geworski, L., Hofmann, M., Munz, D. L. & Knapp, W. H. Use of recovery coefficient as a test of system linearity of response in positron emission tomography (PET). Physics in Medicine and Biology 47, 1237–1254 (2002).
pubmed: 12030553
doi: 10.1088/0031-9155/47/8/302
Catafau, A. M. et al. Impact of dopamine transporter SPECT using123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov. Disord. 19, 1175–1182 (2004).
pubmed: 15390019
doi: 10.1002/mds.20112
Catafau, A. M., Pérez, V., Penengo, M. M. & Al., E. SPECT of Serotonin Transporters Using 123 I-ADAM: Optimal Imaging Time After Bolus Injection and Long-Term Test – Retest in Healthy Volunteers. J Nucl Med 46, 1301–1310 (2005).
pubmed: 16085586
Kuikka, J. T. Quantitative accuracy of serotonergic neurotransmission imaging with high-resolution 123I SPECT. NuklearMedizin 43, 185–189 (2004).
pubmed: 15586213
doi: 10.1055/s-0038-1623914
LECKMAN, J. F. et al. The Yale Global Tic Severity Scale: Initial Testing of a Clinician-Rated Scale of Tic Severity. J. Am. Acad. Child Adolesc. Psychiatry 28, 566–573 (1989).
pubmed: 2768151
doi: 10.1097/00004583-198907000-00015
Goodman, W. K. et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability. Arch. Gen. Psychiatry 46, 1006–1011 (1989).
pubmed: 2684084
doi: 10.1001/archpsyc.1989.01810110048007
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. An Inventory for Measuring Depression. Arch. Gen. Psychiatry 4, 561–571 (1961).
pubmed: 13688369
doi: 10.1001/archpsyc.1961.01710120031004
Laux, L., Glanzmann, P., Schaffner, P. & Spielberger, C. Das State-Trait-Angstinventar: STAI. Weinheim: Beltz (1981).
Christiansen, H. et al. German validation of the Conners Adult ADHD Rating Scales-self-report (CAARS-S) I: Factor structure and normative data. Eur. Psychiatry 26, 100–107 (2011).
pubmed: 20619613
doi: 10.1016/j.eurpsy.2009.12.024
Retz-Junginger, P. et al. Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults. Nervenarzt 73, 830–838 (2002).
pubmed: 12215873
doi: 10.1007/s00115-001-1215-x
Derogatis, L. R., Lipman, R. S. & Covi, L. The SCL-90: An outpatient psychiatric rating scale. Psychopharmacol. Bull. 9, 13–28 (1973).
pubmed: 4682398
Lehrl, S., Triebig, G. & Fischer, B. Multiple choice vocabulary test MWT as a valid and short test to estimate premorbid intelligence. Acta Neurol. Scand. 91, 335–345 (1995).
pubmed: 7639062
doi: 10.1111/j.1600-0404.1995.tb07018.x